AACI President Aims to Integrate Treatment Advances in Community
Stanton L. Gerson, MD, director of the Case Comprehensive Cancer Center and University Hospitals Seidman Cancer Center, in Cleveland, was installed as the new president of the Association of American Cancer Institutes during AACI’s annual meeting in Chicago, held October 23-25.
At the meeting, Dr. Gerson launched his two-year term with a presentation outlining plans for his presidential initiative, which will address a major objective of the Obama Administration’s Cancer Moonshot initiative: Promoting collaborations with researchers, doctors and patients to improve patient outcomes and health care value in the community. A message from Dr. Gerson providing details about the initiative is available here
“The need to facilitate this process is especially great at community points of care where access to newer technology, decision-making expertise to handle “omics” and other advanced diagnostics, clinical trials, or multidisciplinary care may lag that available at larger cancer center sites,” Dr. Gerson said.
To meet that challenge, Dr. Gerson proposed marshalling the collaborative and synergistic knowledge and experience of AACI cancer centers to create a model of care that can provide access to patients currently seen in the community.
“AACI views as a priority the advancement of integrated patient care, expansion of individual cancer center networks to improve clinical trials access, and working across centers to share best practices,” said AACI Executive Director Barbara Duffy Stewart. “I look forward to Stan’s expanded leadership role with AACI and to supporting his efforts to achieve these goals.”
Dr. Gerson has been an active member of AACI for the past 14 years, including service on the board of directors (2007 - 2009). A graduate of Harvard College [magna cum laude] and Harvard Medical School [cum laude], Dr. Gerson completed his residency and hematology and oncology fellowship training at the Hospital of the University of Pennsylvania. As a member of the faculty at Case Western Reserve University he has been involved in the school’s stem cell, hematologic malignancies, and developmental therapeutics programs.
An internationally recognized cancer researcher, Dr. Gerson has received multiple NIH grants and has published more than 236 articles, 270 abstracts, and 37 book chapters. He also has received 18 patents for stem cell and drug discoveries. In addition to his cancer center directorships, Dr. Gerson is the Asa and Patricia Shiverick- Jane Shiverick (Tripp) Professor of Hematological Oncology, Case Western Reserve University School of Medicine, founding director of the National Center for Regenerative Medicine, and Distinguished University Professor at Case Western Reserve University. He is also a member of the NCI Board of Scientific Advisors.